Oestrogel (Estradiol)

Estradiol binds to estrogen receptors α and β in target cells, forming a hormone‑receptor complex that regulates gene transcription. This restores estrogen‑dependent physiological processes, including bone maintenance, regulation of the menstrual cycle, and alleviation of vasomotor symptoms associated with menopause.

The prescribed dose of Oestrogel is determined by the treating clinician according to the patient’s age, severity of symptoms, and clinical response. Dosage instructions are provided on the product label and must be followed as directed by a qualified healthcare professional.

Oestrogel is contraindicated during pregnancy because exogenous estrogen can affect fetal development. It is also not recommended for breastfeeding women, as estradiol may pass into breast milk and potentially influence the infant. Women of child‑bearing potential should use effective contraception while on therapy.

To request Oestrogel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Oestrogel delivers estradiol transdermally, bypassing first‑pass metabolism, which can result in more stable serum levels and reduced hepatic effects compared with oral tablets. Oral estradiol may increase hepatic protein synthesis, while the gel may cause local skin reactions. Choice depends on patient preference, risk profile and clinical judgment.

Oestrogel should be stored at room temperature, away from direct sunlight and moisture. Keep the gel in its original sealed container, and avoid freezing. If the product becomes excessively warm, return it to a controlled environment before use to maintain potency.

The gel is applied to clean, dry, intact skin on the upper arms, shoulders, or abdomen. The recommended amount is measured using the supplied applicator or dose‑measuring device, then gently spread over the area and allowed to dry before dressing. Hands should be washed after application to prevent accidental transfer.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, and stroke, as well as an increased risk of hormone‑sensitive cancers like breast or endometrial cancer. Patients should be monitored for signs of blood clots, unexplained pain, or abnormal bleeding, and therapy should be discontinued if severe adverse events occur.

Oestrogel is contraindicated in women with active or a history of estrogen‑dependent malignancies, unexplained vaginal bleeding, known thrombophilic disorders, severe liver disease, or those who are pregnant or breastfeeding. It should also be avoided in individuals with hypersensitivity to estradiol or any component of the gel formulation.